Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Venous thromboembolism among cancer patients receiving chimeric antigen receptor-T cell therapy.

Rahul Mishra, Sachi Singhal, Barry Meisenberg Jun 01, 2025 pp. 11179-11179 10.1200/jco.2025.43.16_suppl.11179

11179 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of advanced cancers. Although, immune side effects (IC...

Validation of generative AI models’ performance on patient education quizzes: Hormone-related symptoms of cancer care.

Claire Dvorak, Jeffrey R Smith, Nikita C. Shah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13881

e13881 Background: To evaluate the clinical reliability and accuracy of generative AI models when answering patient-level educational quizzes on hormone-r...

ABLE-41, a real-world evidence study for bladder cancer patients treated with nadofaragene firadenovec: Baseline patient characteristics and demographics.

Siamak Daneshmand, Daniel Canter, Tracey Lynn Krupski et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16608

e16608 Background: Nadofaragene firadenovec-vncg is the first FDA-approved intravesical nonreplicating adenoviral vector-based gene therapy which delivers...

Factors impacting treatment with a CDK4/6i in first line metastatic HR+/HER2- breast cancer patients.

Stephan B. Rosenfeld, Fred J. Kudrik, Sowjanya Reganti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13079

e13079 Background: The inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i), abemaciclib, palbociclib and ribociclib, are indicated for the treatment...

Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis.

Muntaser Al Zyoud, Osama Mustafa Younis, Mohammad Alkasji et al. Jun 01, 2025 pp. 2511-2511 10.1200/jco.2025.43.16_suppl.2511

2511 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose unique challenges in solid organ transplant (SOT) recip...

An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor.

Sreenivasa R. Chandana, Suzanne George, Ping Chi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps11580

TPS11580 Background: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract. KIT and plate...

Connecting clinical trials with patients using patient navigation: A scoping review.

Olla Hilal, Eliane Yvonne Paglicauan, Ria Patel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13560

e13560 Background: Patient navigation is a promising strategy to improve access to cancer care, but the evidence supporting its role in increasing access...

Genomic characterization of STAS in stage 1 EGFR-mutated NSCLC and prognostic implications.

Stephanie Pei Li Saw, Mengyuan Pang, Clare Patteri et al. Jun 01, 2025 pp. 8029-8029 10.1200/jco.2025.43.16_suppl.8029

8029 Background: Spread through air spaces (STAS) is a poor prognostic factor and was recently introduced as a histologic descriptor in the TNM edition 9...

Discrepancies between germline and somatic laboratories in the reporting of germline cancer predisposition variants.

Brittany Cooper, Frances Di Clemente, Melissa Gandhi et al. Jun 01, 2025 pp. 10568-10568 10.1200/jco.2025.43.16_suppl.10568

10568 Background: Individuals with a cancer diagnosis may not qualify for germline testing to identify cancer predisposition variants due to restrictive t...

Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

Jifang Gong, Chang Liu, Liang Liu et al. Jun 01, 2025 pp. 4010-4010 10.1200/jco.2025.43.16_suppl.4010

4010 Background: Targeting tumor-infiltrating Tregs presents a promising strategy to overcome resistance to immunotherapy in cancer treatment. LM-108 is a...

Social needs and systemic inflammation associated with cancer survival among a historically marginalized population.

Danielle Tomer, Xianhong Xie, Mindy Ginsberg et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13797

e13797 Background: Challenges with social determinants of health (SDoH) have been shown to increase the risk of delays in cancer treatment initiation and...

Allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia adults in complete remission: A systematic review and meta-analysis.

Muhammad Umair Mushtaq, pramod singh, Asad Zaman et al. Jun 01, 2025 pp. 6559-6559 10.1200/jco.2025.43.16_suppl.6559

6559 Background: There is limited data on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT) in T-cell acute Lymphoblastic Leuk...

The efficacy and safety of Surufatinib monotherapy as a third-line treatment for advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study.

Fuxiang Zhou, Lei Yang, Jin Peng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16209

e16209 Background: Hepatocellular carcinoma (HCC) is an aggressive liver cancer with limited treatment options, particularly in advanced stages. Surufatin...

Clinical characteristics of young-onset breast cancer and the role of germline pathogenic variants.

Nara Tashjian, Tara Rao, Tony Luehrs et al. Jun 01, 2025 pp. 10582-10582 10.1200/jco.2025.43.16_suppl.10582

10582 Background: Breast cancer is the most common cancer in young women, with an increasing incidence over the past two decades. This study aims to evalu...

Predictive value of circulating methylated Septin 9 for pathologic complete response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.

Manqian Zhou, Jindong Liu, Qiong Wu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15649

e15649 Background: Prediction of pathologic complete response (pCR) after neoadjuvant radio-chemotherapy (nCRT) is of great importance for locally advance...

Comparative transcriptomic analysis to identify similarities and therapeutic vulnerabilities in olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC).

Elisabetta Xue, Tolulope Tosin Adeyelu, Mark Gordon Evans et al. Jun 01, 2025 pp. 6095-6095 10.1200/jco.2025.43.16_suppl.6095

6095 Background: ONB, SNEC and SNUC are rare sinonasal epithelial/neuroepithelial tumors, underserved by clinical trials, with few treatments available de...

The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ.

Swati Kulkarni, Geoffrey Greene, Luis Blanco et al. Jun 01, 2025 pp. 512-512 10.1200/jco.2025.43.16_suppl.512

512 Background: Conjugated estrogen/bazedoxifene (CE/BZA), the first tissue selective estrogen complex, was developed as a...

Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India.

Subhankar Basak, Bhavana Pathania, Srikanth Thota et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17596

e17596 Background: AssessingHomologous Recombination Deficiency (HRD) is crucial for ovarian cancer patients to benefit from poly(ADP-ribose polymerase) i...

Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803).

Junichiro Yuda, Yukiko Ishiguro, Yasutoshi Kuboki et al. Jun 01, 2025 pp. 7031-7031 10.1200/jco.2025.43.16_suppl.7031

7031 Background: CD19-targeted CAR-T cell therapy has shown remarkable efficacy against relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Howev...

Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features.

Jeeyeon Elizabeth Lee, Sung Joon Park, Won Hwa Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12533

e12533 Background: Temporal radiomic features (TRF) extracted from dynamic contrast-enhanced breast MR (DCE-MR), which provide important information about...

FES and FDG PET imaging performance comparison for potential use in biology-guided radiotherapy for breast cancer.

Grant Gibbard, Ottar Schmitz, Dorine de Jong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12575

e12575 Background: SCINTIX biology-guided radiotherapy (BgRT) uses F18-FDG emissions from lung and bone tumors to direct radiotherapy beamlets almost in r...

Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) among US community oncology patients with prior acalabrutinib therapy.

Jing-Zhou Hou, Gregory A. Maglinte, Xiaoliang Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23265

e23265 Background: Despite higher selectivity of the second-generation Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (acala) compared with the fir...

Osteoradionecrosis as a complication following intensity-modulated radiation therapy or proton therapy in the treatment of oropharyngeal carcinoma.

Edward Christopher Dee, Fan Yang, Annu Singh et al. Jun 01, 2025 pp. 6066-6066 10.1200/jco.2025.43.16_suppl.6066

6066 Background: Osteoradionecrosis (ORN) is a late complication of head and neck radiotherapy (RT) that negatively impacts survivorship. Although there i...

Clinical outcomes of cytomegalovirus infection among patients receiving chimeric antigen receptor T cell therapy.

Muhammad Atif Khan, Muhammad Shafiq, Mehran Ali Khan et al. Jun 01, 2025 pp. 7021-7021 10.1200/jco.2025.43.16_suppl.7021

7021 Background: Chimeric antigen receptor T (CAR-T) cell therapy is a transformative treatment for hematologic malignancies, including multiple myeloma (...

Eliciting the patient perspective: Using design-thinking methodology to assess the utility of incorporating narrative medicine tools in inpatient cancer.

Sabiha Tamima, Somalee Banerjee Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23212

e23212 Background: Integrating narrative medicine (NM) into oncologic care presents a promising opportunity to enhance patient-centered care by addressing...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page